Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/53000
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rodriguez-Perez, Jose C. | |
dc.contributor.author | Garcia-Bello, Miguel A. | |
dc.contributor.author | Anabitarte-Prieto, Aranzazu | |
dc.contributor.author | Companioni, Osmel | |
dc.contributor.author | Novoa-Mogollon, Francisco J. | |
dc.contributor.author | Suarez-Ortega, Saturnino | |
dc.contributor.author | Plaza-Toledano, Celia | |
dc.contributor.author | Rodriguez-Esparragon, Francisco | |
dc.contributor.other | Rodriguez-Perez, J.C. | |
dc.contributor.other | Rodriguez-Esparragon, Francisco | |
dc.contributor.other | Garcia-Bello, Miguel-Angel | |
dc.date.accessioned | 2019-02-04T14:40:36Z | - |
dc.date.available | 2019-02-04T14:40:36Z | - |
dc.date.issued | 2011 | |
dc.identifier.issn | 1064-1963 | |
dc.identifier.uri | http://hdl.handle.net/10553/53000 | - |
dc.description.abstract | We evaluated the anti-hypertensive and anti-albuminuric effect of the angiotensin receptor blocker telmisartan alone and in combination with torasemide and amlodipine. Patients were hypertensive, both diabetics and non-diabetics with persistent microalbuminuria. Our primary endpoint was a change in microalbuminuria levels, while the secondary endpoints were changes in systolic blood pressure (SBP), diastolic blood pressure (DBP), serum creatinine levels, and glomerular filtration rate. After the 16-week treatment period, the patients significantly reduced microalbuminuria levels (76.4 +/- 52.4 mu g/min; p < 0.001), SBP (16.4 +/- 8.7 mmHg; p < 0.001) and DBP (17.7 +/- 5.9 mmHg; p < 0.001). Both diabetics and non-diabetics showed an identical pattern of significance with respect to the whole population. Systolic blood pressure, DBP, and microalbuminuria were significantly reduced as a consequence of therapy, both in diabetics and non-diabetics. | |
dc.publisher | 1064-1963 | |
dc.relation.ispartof | Clinical and Experimental Hypertension | |
dc.source | Clinical And Experimental Hypertension[ISSN 1064-1963],v. 33 (8), p. 506-510 | |
dc.subject.other | Randomized Controlled-Trial | |
dc.subject.other | Blood-Pressure | |
dc.subject.other | Overt Nephropathy | |
dc.subject.other | High-Risk | |
dc.subject.other | Prevention | |
dc.subject.other | Guidelines | |
dc.subject.other | Valsartan | |
dc.subject.other | Losartan | |
dc.subject.other | Events | |
dc.title | Anti-Albuminuric Effects of the Angiotensin AT1 Receptor Blocker Telmisartan in Hypertensive Patients | |
dc.type | info:eu-repo/semantics/Article | |
dc.type | Article | |
dc.identifier.doi | 10.3109/10641963.2011.561900 | |
dc.identifier.scopus | 82455198894 | |
dc.identifier.isi | 000297470200002 | |
dcterms.isPartOf | Clinical And Experimental Hypertension | |
dcterms.source | Clinical And Experimental Hypertension[ISSN 1064-1963],v. 33 (8), p. 506-510 | |
dc.contributor.authorscopusid | 54412956400 | |
dc.contributor.authorscopusid | 54412123900 | |
dc.contributor.authorscopusid | 6506385286 | |
dc.contributor.authorscopusid | 14061836500 | |
dc.contributor.authorscopusid | 12786120600 | |
dc.contributor.authorscopusid | 7003480889 | |
dc.contributor.authorscopusid | 18034771800 | |
dc.contributor.authorscopusid | 6603262370 | |
dc.description.lastpage | 510 | |
dc.identifier.issue | 8 | |
dc.description.firstpage | 506 | |
dc.relation.volume | 33 | |
dc.type2 | Artículo | |
dc.identifier.wos | WOS:000297470200002 | |
dc.contributor.daisngid | 245684 | |
dc.contributor.daisngid | 1700450 | |
dc.contributor.daisngid | 10185782 | |
dc.contributor.daisngid | 2952487 | |
dc.contributor.daisngid | 4992898 | |
dc.contributor.daisngid | 6018799 | |
dc.contributor.daisngid | 9742321 | |
dc.contributor.daisngid | 1305938 | |
dc.identifier.investigatorRID | C-1247-2010 | |
dc.identifier.investigatorRID | D-2810-2013 | |
dc.identifier.investigatorRID | No ID | |
dc.contributor.wosstandard | WOS:Rodriguez-Perez, JC | |
dc.contributor.wosstandard | WOS:Garcia-Bello, MA | |
dc.contributor.wosstandard | WOS:Anabitarte-Prieto, A | |
dc.contributor.wosstandard | WOS:Companioni, O | |
dc.contributor.wosstandard | WOS:Novoa-Mogollon, FJ | |
dc.contributor.wosstandard | WOS:Suarez-Ortega, S | |
dc.contributor.wosstandard | WOS:Plaza-Toledano, C | |
dc.contributor.wosstandard | WOS:Rodriguez-Esparragon, F | |
dc.date.coverdate | Diciembre 2011 | |
dc.identifier.ulpgc | Sí | es |
dc.description.sjr | 0,403 | |
dc.description.jcr | 1,074 | |
dc.description.sjrq | Q2 | |
dc.description.jcrq | Q4 | |
dc.description.scie | SCIE | |
item.fulltext | Sin texto completo | - |
item.grantfulltext | none | - |
crisitem.author.dept | GIR IUIBS: Patología y Tecnología médica | - |
crisitem.author.dept | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.dept | GIR IUCES: Estrategia y Negocios Internacionales | - |
crisitem.author.dept | IU de Cibernética, Empresa y Sociedad (IUCES) | - |
crisitem.author.dept | Departamento de Economía y Dirección de Empresas | - |
crisitem.author.dept | GIR IUSA-ONEHEALTH 5: Reproducción Animal, Oncología y Anestesiología Comparadas | - |
crisitem.author.dept | IU de Sanidad Animal y Seguridad Alimentaria | - |
crisitem.author.orcid | 0000-0003-0023-1063 | - |
crisitem.author.orcid | 0000-0002-2540-5042 | - |
crisitem.author.orcid | 0000-0003-1663-3673 | - |
crisitem.author.parentorg | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.parentorg | IU de Cibernética, Empresa y Sociedad (IUCES) | - |
crisitem.author.parentorg | IU de Sanidad Animal y Seguridad Alimentaria | - |
crisitem.author.fullName | Rodríguez Pérez,José Carlos | - |
crisitem.author.fullName | Suárez Ortega, Sonia María | - |
crisitem.author.fullName | Rodríguez Esparragón,Francisco Javier | - |
Appears in Collections: | Artículos |
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.